Every year the Cleveland Clinic picks its top late stage drug programs in development. This year it selected the following three products:
- Sofosbuvir - Gilead Sciences - hepatitis C
- Seretaxin - Novartis - cardiovascular drug for pregnant women
- Ibrutinib - Pharmacyclics/J&J - cancer
All 3 drugs have been designated as "breakthrough therapies" at FDA. All 3 drugs were also acquired by acquisition or licensing by the current company bringing them to market. Sofosbuvir and ibrutinib were also selected in the Fierce Biotech top 10 biopharma pipeline drugs earlier this month.
Posted by Bruce Lehr Oct 17th 2013.